Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.43 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.43 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787881 | 0.88 | AGXT (0.62) | AGXTADRA2CHTR3APRMT6DRD2 | |
| SCHEMBL8349954 | 0.87 | PRMT6 (0.59) | AGXTADRA2CPRMT6KDM4EALDH1A1 | |
| SCHEMBL13863230 | 0.86 | AGXT (0.57) | AGXTADRA2CHTR3APRMT6DRD2 | |
| SCHEMBL10190904 | 0.85 | PRMT6 (0.62) | AGXTADRA2CPRMT6KDM4EALDH1A1 | |
| SCHEMBL8352129 | 0.84 | CHRNA7 (0.56) | AGXTDRD2KDM4EGAAMAPT | |
| SCHEMBL8349952 | 0.83 | KHK (0.45) | AGXTADRA2CPRMT6KDM4EALDH1A1 | |
| SCHEMBL27659031 | 0.83 | AGXT (0.57) | AGXTADRA2CPLOD2PLOD3PLOD1 | |
| SCHEMBL10190881 | 0.83 | AGXT (0.60) | AGXTADRA2CPRMT6ALDH1A1MAPT | |
| SCHEMBL20671914 | 0.83 | ADRB1 (0.57) | HTR3ADRD2ALDH1A1MAPTHTR6 | |
| SCHEMBL8222798 | 0.82 | AGXT (0.63) | AGXTADRA2CHTR3APRMT6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | AGXT 520/4885ADRA2C 4806/4885HTR3A 2020/4885 |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | AGXT 2826/4885ADRA2C 1957/4885HTR3A 3857/4885 |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | AGXT 2826/4885ADRA2C 1957/4885HTR3A 3857/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | AGXT 2826/4885ADRA2C 1957/4885HTR3A 3857/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | AGXT 600/4885ADRA2C 4284/4885HTR3A 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.